Thalidomide in the treatment of multiple myeloma

Best Practice and Research: Clinical Haematology

Volumn 20, Issue 4, 2007, Pages 681-699

  Kastritis, Efstathios ^a   Dimopoulos, Meletios A ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

chemotherapy; dexamethasone; DVT; maintenance; myeloma; neurotoxicity; refractory; relapse; thalidomide; untreated

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; BORTEZOMIB; CISPLATIN; CREATINE KINASE; CYCLOPHOSPHAMIDE; CYTOKINE; DEXAMETHASONE; DOXORUBICIN; ENOXAPARIN; ETOPOSIDE; INTERFERON; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; PAMIDRONIC ACID; PREDNISONE; THALIDOMIDE; THYROTROPIN; THYROXINE; VINCRISTINE; WARFARIN;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ATAXIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; AUTONOMIC NEUROPATHY; BONE MARROW TOXICITY; BRADYCARDIA; CANCER INHIBITION; CANCER RELAPSE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFUSION; CONSTIPATION; CONTINUOUS INFUSION; CREATINE KINASE BLOOD LEVEL; CYTOKINE PRODUCTION; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SOLUBILITY; DRUG WITHDRAWAL; EPIDERMOLYSIS; ERYTHEMA MULTIFORME; ERYTHRODERMA; EVENING DOSAGE; HEMODIALYSIS; HUMAN; HYPERKALEMIA; HYPERLIPIDEMIA; HYPOTHYROIDISM; IMMUNOMODULATION; INSOMNIA; KIDNEY FAILURE; LIVER TOXICITY; LOW DRUG DOSE; MACULOPAPULAR RASH; MAINTENANCE THERAPY; MALAISE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE ATROPHY; MUSCLE CRAMP; MUSCLE WEAKNESS; NERVE INJURY; NEUROTOXICITY; NEUTROPENIA; OPTIMAL DRUG DOSE; PARESTHESIA; PATIENT MONITORING; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PRURITUS; PULMONARY HYPERTENSION; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; SKIN EXFOLIATION; SYNCOPE; TERATOGENICITY; THYROTROPIN BLOOD LEVEL; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION; TREMOR; VENOUS THROMBOEMBOLISM;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; HUMANS; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THALIDOMIDE;

EID: 36749084553     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2007.09.001     Document Type: Review

References (98)

1. Singhal S., Mehta J., Desikan R., et al. Antitumor activity of thalidomide in refractory multiple myeloma. The New England Journal of Medicine 341 21 (1999) 1565-1571
2. Teo S.K., Colburn W.A., Tracewell W.G., et al. Clinical pharmacokinetics of thalidomide. Clinical Pharmacokinetics 43 5 (2004) 311-327
3. Eriksson T., Hoglund P., Turesson I., et al. Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis. The Journal of Pharmacy and Pharmacology 55 12 (2003) 1701-1706
4. Bauer K.S., Dixon S.C., and Figg W.D. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochemical Pharmacology 55 11 (1998) 1827-1834
5. Teo S.K., Scheffler M.R., Kook K.A., et al. Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women. Biopharmaceutics & Drug Disposition 21 1 (2000) 33-40
6. Eriksson T., Bjorkman S., and Hoglund P. Clinical pharmacology of thalidomide. European Journal of Clinical Pharmacology 57 5 (2001) 365-376
7. Sampaio E.P., Sarno E.N., Galilly R., et al. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. The Journal of Experimental Medicine 173 3 (1991) 699-703
8. Rowland T.L., McHugh S.M., Deighton J., et al. Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells. Immunopharmacology 40 1 (1998) 11-20
9. Moreira A.L., Sampaio E.P., Zmuidzinas A., et al. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. The Journal of Experimental Medicine 177 6 (1993) 1675-1680
10. Corral L.G., Haslett P.A., Muller G.W., et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. Journal of Immunology 163 1 (1999) 380-386
11. Keifer J.A., Guttridge D.C., Ashburner B.P., et al. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. The Journal of Biological Chemistry 276 25 (2001) 22382-22387
12. Haslett P.A., Corral L.G., Albert M., et al. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. The Journal of Experimental Medicine 187 11 (1998) 1885-1892
13. Verbon A., Juffermans N.P., Speelman P., et al. A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans. Antimicrobial Agents and Chemotherapy 44 9 (2000) 2286-2290
14. Davies F.E., Raje N., Hideshima T., et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98 1 (2001) 210-216
15. Geitz H., Handt S., and Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 31 2-3 (1996) 213-221
16. D'Amato R.J., Loughnan M.S., Flynn E., et al. Thalidomide is an inhibitor of angiogenesis. Proceedings of the National Academy of Sciences of the United States of America 91 9 (1994) 4082-4085
17. Dredge K., Marriott J.B., Macdonald C.D., et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. British Journal of Cancer 87 10 (2002) 1166-1172
18. Gupta D., Treon S.P., Shima Y., et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15 12 (2001) 1950-1961
19. Vacca A., Scavelli C., Montefusco V., et al. Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. Journal of Clinical Oncology 23 23 (2005) 5334-5346
20. Payvandi F., Wu L., Haley M., et al. Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner. Cellular Immunology 230 2 (2004) 81-88
21. Zhang H., Vakil V., Braunstein M., et al. Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood 105 8 (2005) 3286-3294
22. Hideshima T., Chauhan D., Shima Y., et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96 9 (2000) 2943-2950
23. Stephens T.D., Bunde C.J., and Fillmore B.J. Mechanism of action in thalidomide teratogenesis. Biochemical Pharmacology 59 12 (2000) 1489-1499
24. Mitsiades N., Mitsiades C.S., Poulaki V., et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 99 12 (2002) 4525-4530
25. Badros A.Z., Siegel E., Bodenner D., et al. Hypothyroidism in patients with multiple myeloma following treatment with thalidomide. American Journal of Medicine 112 5 (2002) 412-413
26. Dimopoulos M.A., and Eleutherakis-Papaiakovou V. Adverse effects of thalidomide administration in patients with neoplastic diseases. American Journal of Medicine 117 7 (2004) 508-515
27. Hall V.C., El-Azhary R.A., Bouwhuis S., et al. Dermatologic side effects of thalidomide in patients with multiple myeloma. Journal of the American Academy of Dermatology 48 4 (2003) 548-552
28. Rajkumar S.V., Hayman S., Gertz M.A., et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. Journal of Clinical Oncology 20 21 (2002) 4319-4323
29. Rajkumar S.V., Gertz M.A., and Witzig T.E. Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma. The New England Journal of Medicine 343 13 (2000) 972-973
30. Barlogie B., Desikan R., Eddlemon P., et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 98 2 (2001) 492-494
31. Dimopoulos M.A., Zervas K., Kouvatseas G., et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Annals of Oncology 12 7 (2001) 991-995
32. Palumbo A., Giaccone L., Bertola A., et al. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 86 4 (2001) 399-403
33. Alexanian R., Weber D., Anagnostopoulos A., et al. Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma. Seminars in Hematology 40 4 Suppl. 4 (2003) 3-7
34. Garcia-Sanz R., Gonzalez-Porras J.R., Hernandez J.M., et al. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia 18 4 (2004) 856-863
35. Dimopoulos M.A., Hamilos G., Zomas A., et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. The Hematology Journal 5 2 (2004) 112-117
36. Zangari M., Siegel E., Barlogie B., et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 100 4 (2002) 1168-1171
37. Rajkumar S.V., Blood E., Vesole D., et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. Journal of Clinical Oncology 24 3 (2006) 431-436
38. Palumbo A., Bringhen S., Caravita T., et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367 9513 (2006) 825-831
39. Zangari M., Anaissie E., Barlogie B., et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 98 5 (2001) 1614-1615
40. Barlogie B., Tricot G., Anaissie E., et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. The New England Journal of Medicine 354 10 (2006) 1021-1030
41. Zangari M., Barlogie B., Thertulien R., et al. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. Clinical Lymphoma 4 1 (2003) 32-35
42. Zangari M., Saghafifar F., Mehta P., et al. The blood coagulation mechanism in multiple myeloma. Seminars in Thrombosis and Hemostasis 29 3 (2003) 275-282
43. Elice F., Fink L., Tricot G., et al. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. British Journal of Haematology 134 4 (2006) 399-405
44. Streetly M., Hunt B.J., Parmar K., et al. Markers of endothelial and haemostatic function in the treatment of relapsed myeloma with the immunomodulatory agent Actimid (CC-4047) and their relationship with venous thrombosis. European Journal of Haematology 74 4 (2005) 293-296
45. Ward C.M., Yen T., Harvie R., et al. Elevated levels of factor VIII and von Willebrand Factor after thalidomide treatment for malignancy: relationship to thromboembolic events. The Hematology Journal 4 (2003) S251 [abstract 365; suppl]
46. Zangari M., Barlogie B., Anaissie E., et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. British Journal of Haematology 126 5 (2004) 715-721
47. Weber D., Rankin K., Gavino M., et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. Journal of Clinical Oncology 21 1 (2003) 16-19
48. Minnema M.C., Breitkreutz I., Auwerda J.J., et al. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia 18 12 (2004) 2044-2046
49. Baz R., Li L., Kottke-Marchant K., et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clinic Proceedings 80 12 (2005) 1568-1574
50. Yakoub-Agha I., Attal M., Dumontet C., et al. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients-report of the Intergroupe Francophone du Myelome (IFM). The Hematology Journal 3 4 (2002) 185-192
51. Neben K., Moehler T., Benner A., et al. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clinical Cancer Research 8 11 (2002) 3377-3382
52. Schey S.A., Cavenagh J., Johnson R., et al. An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment. Leukemia Research 27 10 (2003) 909-914
53. Tosi P., Zamagni E., Cellini C., et al. Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. European Journal of Haematology 74 3 (2005) 212-216
54. Chaudhry V., Cornblath D.R., Corse A., et al. Thalidomide-induced neuropathy. Neurology 59 12 (2002) 1872-1875
55. Mileshkin L., Stark R., Day B., et al. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. Journal of Clinical Oncology 24 27 (2006) 4507-4514
56. Cavaletti G., Beronio A., Reni L., et al. Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study. Neurology 62 12 (2004) 2291-2293
57. Hus M., Dmoszynska A., Soroka-Wojtaszko M., et al. Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica 86 4 (2001) 404-408
58. Tosi P., Zamagni E., Cellini C., et al. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica 87 4 (2002) 408-414
59. Mileshkin L., Biagi J.J., Mitchell P., et al. Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood 102 1 (2003) 69-77
60. Waage A., Gimsing P., Juliusson G., et al. Early response predicts thalidomide efficiency in patients with advanced multiple myeloma. British Journal of Haematology 125 2 (2004) 149-155
61. Hus I., Dmoszynska A., Manko J., et al. An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma. British Journal of Cancer 91 11 (2004) 1873-1879
62. Grosbois B., Bellisant E., Moreau P., et al. Thalidomide (Thal) in the treatment of advanced multiple myeloma (MM). A prospective study of 120 patients. [abstract 689]. Blood 98 (2001)
63. Yakoub-Agha I., Doyen C., Hulin C., et al. A multicenter prospective randomized study testing non-inferiority of thalidomide 100 mg/day as compared with 400 mg/day in patients with refractory/relapsed multiple myeloma: results of the final analysis of the IFM 01-02 study. [Meeting Abstracts]. Journal of Clinical Oncology 24 18 Suppl (2006) 7520
64. Weber D., Delasalle K., Giralt S., et al. Thalidomide alone or with dexamethasone for multiple myeloma. Blood 94 (1999) 604a
65. Anagnostopoulos A., Weber D., Rankin K., et al. Thalidomide and dexamethasone for resistant multiple myeloma. British Journal of Haematology 121 5 (2003) 768-771
66. Palumbo A., Falco P., Ambrosini M.T., et al. Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant. European Journal of Haematology 75 5 (2005) 391-395
67. Fermand J-P, Jaccard A, Macro M, et al. A randomized comparison of Dexamethasone + Thalidomide (Dex/Thal) vs Dex + Placebo (Dex/P) in patients (pts) with relapsing multiple myeloma (MM). ASH Annual Meeting Abstracts 2006;108(11):3563.
68. Glasmacher A, Hahn C, Hoffmann F, et al. Thalidomide in relapsed or refractory patients with multiple myeloma: monotherapy or combination therapy? A report from systematic reviews. ASH Annual Meeting Abstracts 2005;106(11):5125.
69. Moehler T.M., Neben K., Benner A., et al. Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood 98 13 (2001) 3846-3848
70. Lee C.K., Barlogie B., Munshi N., et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. Journal of Clinical Oncology 21 14 (2003) 2732-2739
71. Kropff M.H., Lang N., Bisping G., et al. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. British Journal of Haematology 122 4 (2003) 607-616
72. Offidani M., Corvatta L., Marconi M., et al. Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study. Haematologica 91 1 (2006) 133-136
73. Kyriakou C., Thomson K., D'Sa S., et al. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. British Journal of Haematology 129 6 (2005) 763-770
74. Richardson P.G., Barlogie B., Berenson J., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. The New England Journal of Medicine 348 26 (2003) 2609-2617
75. Zangari M, Barlogie B, Burns MJ, et al. Velcade (V)-Thalidomide (T)-Dexamethasone (D) for advanced and refractory Multiple Myeloma (MM): long-term follow-up of phase I-II trial UARK 2001-37: Superior outcome in patients with normal cytogenetics and no prior T. ASH Annual Meeting Abstracts 2005;106(11):2552.
76. Palumbo A., Ambrosini M.T., Benevolo G., et al. Bortezomib, melphalan, prednisone and thalidomide for relapsed multiple myeloma. Blood (2006)
77. Terpos E, Anagnostopoulos A, Kastritis E, et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide (vmdt) is an effective treatment for relapsed/refractory myeloma: results of a phase II clinical trial. ASH Annual Meeting Abstracts 2005;106(11):363.
78. Rajkumar S.V., Gertz M.A., Lacy M.Q., et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia 17 4 (2003) 775-779
79. Cavo M., Zamagni E., Tosi P., et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 89 7 (2004) 826-831
80. Abdelkefi A., Torjman L., Ben Romdhane N., et al. First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma. Bone Marrow Transplantation 36 3 (2005) 193-198
81. Rajkumar SV, Hussein M, Catalano J, et al. A randomized, double-blind, placebo-controlled trial of thalidomide plus dexamethasone versus dexamethasone alone as primary therapy for newly diagnosed multiple myeloma. ASH Annual Meeting Abstracts 2006;108(11):795.
82. Cavo M., Zamagni E., Tosi P., et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 106 1 (2005) 35-39
83. Macro M, Divine M, Uzunhan Y, et al. Dexamethasone + Thalidomide (Dex/Thal) compared to VAD as a pre-transplant treatment in newly diagnosed multiple myeloma (MM): a randomized trial. ASH Annual Meeting Abstracts 2006;108(11):57.
84. Goldschmidt H, Sonneveld P, Breitkreuz I, et al. HOVON 50/GMMG-HD3-trial: phase III study on the effect of thalidomide combined with high dose melphalan in myeloma patients up to 65 years. ASH Annual Meeting Abstracts 2005;106(11):424.
85. Zervas K, Mihou D, Katodritou I, et al. VAD-doxil vs.VAD-doxil plus thalidomide as initial treatment in patients with multiple myeloma: a multicenter randomized trial of the Greek Myeloma Study Group. ASH Annual Meeting Abstracts 2006;108(11):794.
86. Palumbo A., Bertola A., Musto P., et al. Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma. Cancer 104 7 (2005) 1428-1433
87. Facon T., Mary J., Harousseau J., et al. Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. [Meeting Abstracts]. Journal of Clinical Oncology 24 18 Suppl (2006) 1
88. Hulin C., Virion J., Leleu X., et al. Comparison of melphalan-prednisone-thalidomide (MP-T) to melphalan-prednisone (MP) in patients 75 years of age or older with untreated multiple myeloma (MM). Preliminary results of the randomized, double-blind, placebo controlled IFM 01-01 trial. [Meeting Abstracts]. Journal of Clinical Oncology 25 18 Suppl (2007) 8001
89. Dimopoulos M.A., Anagnostopoulos A., Terpos E., et al. Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma. Haematologica 91 2 (2006) 252-254
90. Offidani M., Corvatta L., Piersantelli M.N., et al. Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. Blood 108 7 (2006) 2159-2164
91. Hicks L, Haynes A, Reece DE, et al. A systematic review and meta-analysis of thalidomide in patients with previously untreated multiple myeloma. ASH Annual Meeting Abstracts 2006;108(11):3570.
92. Alexanian R., Weber D., Giralt S., et al. Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. Annals of Oncology 13 7 (2002) 1116-1119
93. Stewart A.K., Chen C.I., Howson-Jan K., et al. Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. Clinical Cancer Research 10 24 (2004) 8170-8176
94. Feyler S, Rawstron A, Jackson G, et al. Thalidomide maintenance following high dose therapy in multiple myeloma: a UK Myeloma Forum Phase 2 Study. ASH Annual Meeting Abstracts 2005;106(11):641.
95. Hussein MA, Jakubowiak AJ, Bolejack V, et al. S0204: Melphalan (MEL)-Based Tandem Autotransplants (TAT) for Multiple Myeloma (MM) with Thalidomide/Dexamethasone (TD) Induction and Thalidomide/Prednisone (TP) maintenance: a Phase II Trial of the Southwest Oncology Group. ASH Annual Meeting Abstracts 2006;108(11):3088.
96. Attal M., Harousseau J.L., Leyvraz S., et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108 10 (2006) 3289-3294
97. Spencer A, Prince M, Roberts AW, et al. First Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) trial of thalidomide and alternate day prednisolone following Autologous Stem Cell Transplantation (ASCT) for patients with Multiple Myeloma (ALLG MM6). ASH Annual Meeting Abstracts 2006;108(11):58.
98. Abdelkefi A, Ladeb S, Ben Othman T, et al. Timing of second autologous transplantations in multiple myeloma: results of a multicenter sequential randomized clinical trial. ASH Annual Meeting Abstracts 2006;108(11):59.